Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Dr. Lal PathLabs Limited ( (IN:LALPATHLAB) ) just unveiled an update.
Dr. Lal PathLabs Limited has announced the voluntary liquidation of its wholly-owned subsidiary, Suburban Diagnostics (India) Private Limited. As part of this process, Suburban’s entire business operations have been consolidated into Dr. Lal PathLabs, effective from March 18, 2025. This strategic move is expected to streamline operations and enhance the company’s market positioning by integrating Suburban’s business, which contributed 7.37% to the turnover and 7.05% to the net worth of Dr. Lal PathLabs in the last financial year.
More about Dr. Lal PathLabs Limited
Dr. Lal PathLabs Limited operates in the healthcare diagnostics industry, offering a wide range of pathology and diagnostic services. The company is known for its extensive network of laboratories and collection centers across India, focusing on providing high-quality diagnostic services to its customers.
YTD Price Performance: -16.43%
Average Trading Volume: 3,530
Current Market Cap: 211.4B INR
See more insights into LALPATHLAB stock on TipRanks’ Stock Analysis page.